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COLORECTAL CANCER
Placenta growth factor expression is correlated with survival
of patients with colorectal cancer
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Background: Overexpression of vascular endothelial growth factor (VEGF) correlates with vascularity,
metastasis, and proliferation in colorectal cancer but the role of its homologue, placenta growth factor
(PlGF), is unknown. The aim of this study was to evaluate expression and clinical implications of PlGF in
colorectal cancer.
Methods: We investigated 74 tumour/non-tumour pairs of colorectal cryosections. Clinical staging was
based on the UICC-TNM classification. Expression levels of mRNA for PlGF and VEGF were analysed with
quantitative real time reverse transcription-polymerase chain reaction. Proteins were analysed by
immunohistochemical staining and enzyme linked immunoabsorbant assay. Analysis of the differences in
PlGF and VEGF levels between tumour and non-tumour tissues in the same patient were performed by
paired t test; differences between localised and advanced disease patients by the Mann-Whitney, x2, and
Fisher’s exact tests and survival curves by the Kaplan-Meier method.
Results: Expression levels for both growth factors were significantly higher in tumour than in non-tumour
tissues (p(0.001). The ratio of PlGF expression in tumour to non-tumour in the advanced disease group
was significantly higher than for the localised disease group (p = 0.009). Patients with more tumour PlGF
mRNA had shorter survival (p = 0.028). The majority of PlGF was expressed in tumour cells.
Conclusions: Our results suggest that PlGF expression correlates with disease progression and patient
survival and may be used as a prognostic indicator for colorectal cancer.
A
ngiogenesis, the process of new blood vessel formation,
is a critical step in tumour growth and progression and
is regulated by tumour cell derived growth factors that
act specifically on vascular endothelial cells.1 It has been
shown that rapid exponential growth of tumours does not
begin until neovascularisation occurs. Many angiogenic
factors have been identified that regulate angiogenesis in
colon cancer. Vascular endothelial growth factor (VEGF) has
been shown to be upregulated in the progression from non-
metastatic to metastatic colon cancers.2–7 Shiraishi et al
showed that levels of VEGF were highest in carcinomas
followed by those in adenomas, with the lowest in non-
neoplastic mucosa.3 Takahashi et al demonstrated that
expression levels of VEGF and vessel counts in primary
metastatic tumours were higher than those in non-metastatic
neoplasms and these two factors directly correlated with the
extent of neovascularisation and degree of proliferation.5
Furthermore, high levels of VEGF expression and elevated
vessel counts were found to correlate with recurrence and
metastasis of colon cancer, suggesting that VEGF expression
could serve as an indicator of colorectal cancer prognosis.
However, most studies showed that VEGF expression is not a
good predictor of prognosis.4 8 9
Placenta growth factor (PlGF), a dimeric glycoprotein with
53% homology to VEGF,10 11 binds to VEGF receptor 1, but
not to VEGF receptor 2, and may function by modulating
VEGF activity.12 Exogenous PlGF stimulates angiogenesis
and induces vascular permeability when coinjected with
VEGF.13 14 The angiogenic activity of PlGF may be initiated by
displacement of VEGF from the VEGF receptor 1 sink, thus
increasing the VEGF available for activation of VEGF receptor
2.13 15 Absence of PlGF had a negligible effect on vascular
development and normal embryogenesis, as demonstrated in
PlGF knockout mice, but such a deficiency could reduce
collateral vascular growth under pathological conditions,
such as ischaemia, inflammation, and cancer.15
PlGF expression has been reported in hypervascular renal
cell carcinomas and in some thyroid and germ cell tumours.16
Donnini et al demonstrated that PlGF was highly upregulated
in a subset of human meningiomas.17 Recently, Adini et al
found that overexpression of PlGF leads to tumour growth as
well as vascular formation, induces expression of survival
genes, and inhibits apoptosis in vitro. They proposed that
PlGF contributes to tumour angiogenesis by providing
functions needed for endothelial cell survival.18 However,
the correlations between PlGF, angiogenesis, metastasis, and
prognosis in colon cancer are not clear. The goal of our study
was to evaluate correlations among these factors.
MATERIALS AND METHODS
Materials
Seventy four tumour and non-tumour pairs of colorectal
cryosections were included from samples collected from
September 2000 to June 2003, following the rules set forth by
the ethics committee of the National Taiwan University
Hospital. All tissues were freshly frozen or immersed in OCT,
and kept at 280 C˚ until use. Expression levels of PlGF or
VEGF were analysed by quantitative reverse transcription-
polymerase chain reaction (RT-PCR) and the ratio of
expression levels in the tumour tissue to those in non-
tumour tissue was calculated. Clinical staging of cancers was
determined based on the UICC-TNM classification. All
patients received identical treatment programmes in this
study. No preoperation chemotherapy or radiotherapy had
been given while stage III and IV patients were subjected
to postoperative chemotherapy with 5-fluorouracil and
Abbreviations: VEGF, vascular endothelial growth factor; PlGF,
placenta growth factor; LCM, laser capture microdissection; PBS,
phosphate buffered saline; ELISA, enzyme linked immunoabsorbant
assay
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leucovorin. Stages I and II were collectively termed as the
localised disease group and stages III and IV as the advanced
disease group in this study. Follow up duration was defined
as the period between the operation date and day of the last
visit, according to the patient’s chart.
Quantitative RT-PCR
Total RNA was isolated using an RNA extraction kit (Qiagen
Inc., California, USA) from tissue homogenised with Trizol
(Invitrogen Inc., Carlsbad, California, USA), according to the
manufacturer’s instructions. For confirming expression levels
of PlGF in tumour tissue, cells were collected from 15 stage
III/IV patients by laser capture microdissection (LCM), as
previously reported.19 Briefly, 5 mm sections tissue were
mounted on silicon coated slides. Slides were cleared in
xylene and dehydrated in graded alcohols. After staining
with haematoxylin-eosin, LCM using a PixCell I system
(Arcturus Engineering, Mountain View, California, USA) was
used to separate tumours and normal cells. LCM parameters
included a laser power of 90 mW, laser pulse duration of
1.2 ms, and laser spot size of 7.5–15 mm in diameter. A cap
devised by Arcturus Engineering was used for the transfer
film. RNA was extracted and isolated using the PicoPure RNA
Isolation kit (Arcturus Engineering) according to the
manufacturer’s instructions.
Primers and probes were designed using the Primer
Express program (Perkin-Elmer Applied Biosystems,
California, USA) and purchased from the same vendor. The
primers used, based on the cDNA sequence of PlGF, were as
follows: forward primer 59-GCG ATG AGA ATC TGC ACT GTG
T-39; reverse primer 59-TCC CCA GAA CGG ATC TTT AGG-39.
The sequence of the probe used to detect and quantify the RT-
PCR product was 59-AGA CGG CCA ATG TCA CCA TGC AGC-
39. The primers and probe used for VEGF mRNA were as
follows: forward primer 59-TAC CTC CAC CAT GCC AAG TG -
39; reverse primer 59-GAT GAT TCT GCC CTC CTC CTT-39;
probe 59-TCC CAG GCT GCA CCC ATG GC-39. The primers
and probe used for the GAPDH (internal control) mRNA were
as follows: forward primer 59-GAA GGT GAA GGT CGG AGT -
39; reverse primer 59-GAA GAT GGT GAT GGG ATT TC-39;
probe 59-CAA GCT TCC CGT TCT CAG CC- 39.
Samples to produce the standard curve for real time RT-
PCR were prepared by serial dilution of a specific RNA sample
to cover the range 100 ng to 0.1 ng. Aliquots of the serially
diluted samples were saved and stored at 280 C˚ until use.
Expression levels of the target gene were measured using
quantitative real time RT-PCR in the ABI Prism 7700
Sequence Detection System (Applied Biosystems) following
the manufacturer’s protocol. The amplification mixture
(25 ml) contained 10 ng of sample RNA (5 ml), 26 Master
Mix without UNG (12.5 ml), 406 MultiScribe and RNase
inhibitor mix (0.625 ml), 9 mM forward and reverse primers
(5 ml), and 2 mM probe (2.5 ml) (Perkin-Elmer Applied
Biosystems). Thermal cycling parameters were as follows:
one cycle of 30 minutes at 48 C˚, one cycle of 10 minutes at
95 C˚ for deactivation, and 40 cycles at 95 C˚ for 15 seconds
and at 60 C˚ for one minute for the melting, annealing, and
extending phases of the PCR reaction, respectively. Each
assay included standard curve samples in duplicate, a no
template control, and approximately 10 ng of sample total
RNA in triplicate. Any sample with a coefficient of variation
above 10% was retested. Fluorescence emitted by the reporter
dye (FAM-6-carboxy-fluorescein, fluorescence emission peak
at 518 nm) was detected online in real time with the ABI
Prism 7700 Sequence Detection System. Threshold cycle (CT)
is the fractional cycle number at which the fluorescence
generated by cleavage of the probe exceeds a fixed level above
baseline. For a chosen threshold, a smaller starting copy
number results in a higher CT value. In this study, we chose
GAPDH mRNA as an internal control. The relative amount of
tissue PlGF mRNA, standardised against the amount of
GAPDH mRNA, was expressed as –DCT = – [CT(PlGF) –
CT(GAPDH)]. The ratio of the number of PlGF mRNA copies to
the number of GAPDH mRNA copies was then calculated as
22DCT6K, where K is a constant.
Immunohistochemical staining
Serial sections of frozen colon tissues were mounted on poly-
L-lysine coated slides and allowed to dry for 30 minutes
before fixation in 100% acetone for 15 minutes. Tissue
sections were washed for five minutes, three times, in
phosphate buffered saline (PBS), immersed in 2% H2O2 in
methanol for 25 minutes to inactivate endogenous peroxid-
ase, and blocked with 1% bovine serum albumin. Blocked
sections were incubated with antibodies against PlGF, VEGF,
or Flt-1 (Santa Cruz Biotechnology, Inc., Heidelberg,
Germany) at dilutions of 1:25, 1:50, and 1:25, respectively,
for two hours at room temperature, washed with PBS,
reacted with biotinylated secondary antibody with antigoat
antibody (dilution of 1:500; Santa Cruz Biotechnology, Inc.)
for PlGF, and antirabbit antibody (dilution of 1:500; Vector
Laboratories Inc, Burlingame, California, USA) for VEGF and
Flt-1 for one hour, followed by incubation with streptavidin
conjugated horseradish peroxidase (peroxidase substrate kit,
DAB; Vector Laboratories Inc.) which was used to reveal
localisation of the antibodies, and tissues were counter-
stained with Mayer’s haematoxylin.
ELISA (enzyme linked immunoabsorbant assay)
Protein lysate from each specimen was prepared using 10 mg
tissue cut into tiny pieces, suspended in cell lysis buffer
(0.15 M Nacl; 0.1 M Tris, pH 8.0; 1 mM EDTA, pH 8.0; 1 mM
PMSF) and mechanically homogenised with a polytron PT
3000 (30 000 rpm for one minute). Protein lysate was kept at
280 C˚ until use. Concentrations of PlGF in tumour and non-
tumour tissues were quantified using a ‘‘Quantikine’’ human
PlGF immunoassay (R&D Systems, Inc., Minneapolis,
Minnesota, USA). Diluted protein lysate was incubated in
triplicates overnight at 4 C˚ on microtitre plates coated with a
murine monoclonal antibody against human PlGF. Unbound
proteins were washed off, and an enzyme linked polyclonal
antibody specific for PlGF was added to ‘‘sandwich’’ the PlGF
immobilised during the first incubation. A substrate solution
for horseradish peroxidase was added, and colour developed
in proportion to the amount of antibody bound PlGF.
Absorbance of the colour was read at 450 nm. A standard
curve, consisting of known amounts of PlGF, was carried
through the above procedure, and concentrations of PlGF in
the unknown samples were determined from this standard
curve. Concentrations of PlGF were expressed as pg/mg of
protein.
Data analysis
Differences in PlGF and VEGF mRNA levels, and PlGF
protein levels between tumour and non-tumour tissues in the
same patient were analysed using a paired t test while
differences between localised disease and advanced disease
patients were analysed using the Mann-Whitney, x2, and
Fisher’s exact tests. Correlations between PlGF or VEGF
expression levels and clinical stages, and PlGF expression
levels between mRNA and protein, were analysed by
Spearman’s correlation coefficient. A survival curve was
obtained using the Kaplan-Meier method. Differences in
cancer specific survival time for patients with tumours with
high or low expression levels of PlGF or VEGF were analysed
using the Breslow test.
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RESULTS
Basic data
A total of 74 colorectal cancer patients, 39 males and 35
females, were included in the study (table 1). There were 14
rectal cancers and 60 colon cancers. However, there were no
significant differences in PlGF, VEGF expression level (either
tumour tissue or tumour to non-tumour ratio), age, sex, or
cancer specific survival between the rectal and colon cancer
groups. Age at first diagnosis ranged from 26 to 94 years
(mean 68.4). Follow up for these 74 patients ranged from 1 to
47 months (mean 26.0). During follow up, 14 patients died of
colorectal cancer. According to the UICC-TNM classification,
there were 14 stage I patients, 27 stage II patients, 22 stage III
patients, and 11 stage IV patients. Among these patients,
there were three with synchronous colorectal cancers and six
with metachronous colorectal cancers.
Both PlGF and VEGF mRNA expression were
upregulated in colorectal cancer and the extent of
upregulation correlated with disease progression
Expression levels of PlGF and VEGF in tumour tissues were
higher than in non-tumour tissues (p,0.001 and p=0.001,
respectively). In addition, in 15 patients, RNA extracted from
tumour cells collected by LCM also confirmed the finding
that expression levels of PlGF in tumour cells were higher
than in non-tumour cells. Mean (SEM) 2DCT for tumour
tissue was23.22 (0.35) compared with 20.25 (0.23) for non-
tumour tissue (p,0.001). Tumour to non-tumour ratios for
PlGF and VEGF levels were much higher for the three
synchronous cancer patients than for the mean of all of the
other patients (p,0.001, for both factors). In contrast, the
difference in ratios between metachronous patients and all
patients was not significant. Expression levels of PlGF in
colon cancer tumour tissues increased gradually from stages I
to IV, with 2DCT mean values for each stage of 20.40, 0.50,
0.77, and 1.79, respectively. Expression levels of VEGF in
colon cancer tumour tissues increased gradually from stages
II to IV, with mean values for each stage (2DCT) of 0.54, 0.73,
and 1.28, respectively. Tumour to non-tumour ratios for PlGF
and VEGF also increased gradually from stages I to III (fig 1A,
B). Considering the relationship between histological type
and PlGF and VEGF expression, all 74 tumours were
reviewed and classified. There were seven poorly differen-
tiated, two well differentiated, and 65 moderately differ-
entiated tumours and there were no statistically significant
differences in PlGF or VEGF expression among these three
groups.
A positive correlation was observed between expression
levels of PlGF and VEGF in tumour tissues (r=0.747,
P,0.001) as well as in non-tumour tissues (r=0.67,
p,0.001). The ratio of PlGF level in tumour tissue to PlGF
level in non-tumour tissue showed a positive correlation
(r=0.744, p,0.001) with the ratio of VEGF level in tumour
tissue to VEGF level in non-tumour tissue, as shown in fig 1C.
PlGF, but not VEGF, mRNA expression is a prognostic
marker for colorectal cancer
In this study, 2DCT value of PlGF for the tumour samples
ranged from 26.56 to 4.58, with a median value of 0.87,
whereas values for VEGF ranged from 22.72 to 4.34 (median
0.79). Patients were divided into low and high expression
groups, based on whether they were above or below the
median value. Patients in the high PlGF mRNA expression
group were more likely to have advanced disease than those
in the low expression group (stage IV, p=0.047) (table 1).
The probability of cancer specific survival was significantly
lower in the high PlGF mRNA expression group (mean
survival 35.8 months (95% confidence interval (CI) 30.5–
41.1) than that of the low PlGF mRNA expression group
(mean survival 43.3 months (95% CI 39.8–46.7); Breslow
test, p=0.040) (fig 2A). In contrast, the difference between
the probabilities of cancer specific survival in the high VEGF
mRNA expression group and the low VEGF mRNA expres-
sion group was not statistically significant (p=0.41) (fig 2B).
Table 1 Summary of the demographic data, placenta growth factor (PlGF), vascular endothelial growth factor (VEGF) mRNA
expression, and survival
Localised disease Advanced disease
Total
(n = 74) p Value
Stage I
(n = 14)
Stage II
(n = 27)
Stage III
(n = 22)
Stage IV
(n = 11)
Sex 0.222
Male 6 13 13 7 39
Female 8 14 9 4 35
Age (y) 74.9 (3.0) 68.8 (3.1) 69.6 (2.6) 62.2 (4.9) 69.2 (1.7) 0.181
Follow up period (month) 24.6 (2.4) 29.6 (2.1) 25.4 (2.7) 20.1 (4.5) 26.0 (1.4) 0.150
Survival`* 0.001
Yes 14 24 18 4 60
No 0 3 4 7 14
2DCT of PlGF
T* 0.19 (0.32) 1.11 (0.42) 0.013
T/NT ratio* 0.42 (0.31) 1.66 (0.30) 0.009
2DCT of VEGF
T 0.65 (0.23) 0.91 (0.30) 0.418
T/NT ratio 0.62 (0.28) 1.07 (0.35) 0.302
PlGF >median1 5 12 12 9 38
Survival*
Yes 28
No 10
PlGF ,median1 9 15 10 2 36
Survival*
Yes 32
No 4
Age and follow up period are presented as means (SEM).
`Differences in survival among different stages was statistically significant.
1Survival between PlGF > median and PlGF ,median was statistically significant with p = 0.028 by the x2 test.
Comparison of localised and advanced disease groups. Sex and survival were analysed using the x2 method and Fisher’s exact test; age, follow up period,2DCT
of PlGF, and 2DCT of VEGF were analysed using the Mann-Whitney test.
*p,0.05.
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For further comparison, patients with stages I and II were
categorised as the localised disease group and patients with
stages III and IV as the advanced disease group. Table 1 also
shows that PlGF expression levels, the ratio between PlGF
levels in tumour tissues and PlGF levels in non-tumour
tissues, and cancer specific survival were significantly
different between the localised disease and advanced disease
groups (p=0.013 and 0.001, respectively). Differences in sex,
age, follow up period, VEGF expression, and ratio between
VEGF levels in tumour tissues and VEGF levels in non-
tumour tissues were not statistically significant. As deaths
were mostly observed for the advanced disease group, we
tried to determine whether there was any independent factor
for predicting outcome in these advanced disease patients.
We found that there was a trend for PlGF expression as a
predictor of survival as the probability of survival was lower
in the high PlGF mRNA expression group (mean survival
30.7 months) than in the low PlGF mRNA expression group
(mean survival 36.5 months; Breslow test, p=0.12) (fig 2C).
However, the difference was not significant due to the small
sample size and short follow up period.
PlGF, VEGF, and Flt-1 localisation in colorectal cancer
Immunohistochemical staining analysis (fig 3) showed that
both PlGF and VEGF were expressed mainly in tumour cells.
In contrast, Flt-1, the receptor for PlGF and VEGF, was
expressed in both tumour cells as well as in endothelial cells.
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Figure 1 Distribution of ratios between expression levels in tumour
tissues and expression levels in non-tumour tissues in different stages of
colorectal cancer. Placenta growth factor (PlGF) (A) and vascular
endothelial growth factor (VEGF) (B) ratios are presented here as 2X,
where X = (2DCT of tumour) 2 (2DCT of non-tumour). (C) Correlation
between ratios of expression levels in tumour tissues and expression
levels in non-tumour tissues. Ratios of VEGF levels from different patients
versus ratios of PlGF levels from the respective patients. PlGF and VEGF
ratio are presented as 2X, where X = (2DCT of tumour) 2 (2DCT of non-
tumour).
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Figure 2 Survival curves in patients with colorectal cancer. (A) Survival
curves of patients with placenta growth factor (PlGF) expression levels
higher or lower than the median value. (B) Survival curves of patients
with vascular endothelial growth factor (VEGF) expression levels higher
or lower than the median value. (C) Survival curves for the advanced
disease group with PlGF expression levels higher or lower than the
median value.
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PlGF protein levels correlated with mRNA levels
Protein levels of PlGF in tumour tissues ranged from 26.6 to
2498.4 pg/mg (mean (SEM) 281.3 (38.8) pg/mg). In corre-
sponding non-tumour tissues, protein levels of PlGF ranged
from 26.6 to 358.4 pg/mg (mean (SEM) 128.7 (8.5) pg/mg).
PlGF protein levels in tumours were significantly higher than
those of corresponding non-tumour tissues (p,0.001)
(fig 4A). PlGF protein expression correlated well with
mRNA from the same tissue (r=0.308, p,0.001) (fig 4B).
DISCUSSION
Angiogenesis is required for tumour growth and metasta-
sis.20–22 Recently, PlGF has been shown to be a key molecule
in the angiogenic switch under pathological conditions,
including cancer.15 In the present study, we demonstrated
that PlGF expression levels were significantly higher in
tumour tissues compared with non-tumour tissues. The ratio
between PlGF levels in tumour tissues and PlGF levels in the
non-tumour tissue correlated well with the stage of colon
cancer. Furthermore, higher PlGF expression in the tumour,
as well as a higher ratio of PlGF levels in tumour tissues to
PlGF levels in non-tumour tissues, correlated with a poorer
prognosis. It has been proposed that PlGF stimulates
angiogenesis through displacement of VEGF from the Flt-1
sink, thereby increasing the fraction of VEGF available for
activation of Flk-1.13 15 Alternatively, PlGF can modulate the
function of VEGF by regulating intermolecular and intra-
molecular crosstalk between Flt-1 and Flk-1.23 Moreover,
PlGF alone can trigger its own signalling, independent of the
VEGF/Flk-1 pathway, and can trigger Flt-1 dependent
functions such as proliferation, apoptosis, and angiogenesis.23
In addition, loss of PlGF activity impaired angiogenesis in
pathological conditions such as ischaemia, inflammation,
and cancer.15 These results suggest that PlGF may be a key
molecule in regulating the angiogenic switch under patho-
logical conditions. These data are consistent with our results
that PlGF expression levels are significantly higher in tumour
tissues than in non-tumour tissues and that the ratio
between PlGF levels in tumour tissues and PlGF levels in
non-tumour tissues correlates with colon cancer stage.
Several studies have demonstrated that VEGF and PlGF
expression correlate with tumour growth and angiogen-
esis.2 4 5 7 13–15 18 In our study, we showed that expression
levels of PlGF and VEGF in tumour tissues were higher than
in non-tumour tissues of the same colorectal cancer patients.
These results suggest that both PlGF and VEGF may play
roles in colorectal cancer formation and tumour progression,
consistent with the hypothesis of Carmeliet et al that PlGF
exerts a synergistic effect on VEGF driven angiogenesis under
pathological conditions.15 VEGF stimulates growth of new
vessels that are fragile, leaky, and prone to regression. PlGF
can recruit smooth muscle cells/precursors, and thereby
stimulate vessel maturation and stabilisation.24 25 Therefore,
PlGF and VEGF should be upregulated in parallel during
angiogenesis to stimulate the formation of mature non-leaky
vessels. PlGF expression could be regulated by oxygen
tension and cytokines.26 However, the mechanism of
increased PlGF expression in colorectal cancer remains
unclear.
Elevated expression of VEGF in tumour tissues of colo-
rectal cancer patients was observed in many studies. There
was generally no correlation between elevated VEGF expres-
sion and patient survival,4–8 18 with only one exception, that of
Lee et al who reported that VEGF correlated with survival.
However, it did not emerge as an independent risk factor in a
multivariate analysis.2 Our studies also showed that VEGF
expression increased in tumour tissues but did not correlate
with survival. In contrast, PlGF expression levels not only
increased in colorectal cancer but also correlated with
survival. This indicates that PlGF, in addition to its
synergistic effect on VEGF driven angiogenesis, may have
its own distinct effect on colorectal cancer. The clinical
implication is that PlGF may be useful as a prognostic
indicator, especially important in TNM stage III and IV
patients. For stage III and IV patients with low PlGF levels,
aggressive treatment is still recommended.
Figure 3 Immunohistochemical stain showed a positive placenta growth factor (PlGF) (A) and vascular endothelial growth factor (VEGF) (B) reaction,
mainly in tumour cells, while Flt-1 (C) protein was expressed in both tumour cells and endothelial cells. A–C, 2006; stage III; arrows, tumour cells;
arrowhead, endothelial cell.
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Figure 4 (A) Protein levels of placenta growth factor (PlGF) were
significantly higher in colorectal tumour tissues than in corresponding
non-tumour tissues, measured by an ELISA method. (B) PlGF protein
expression levels were significantly correlated with mRNA expression
levels.
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Immunohistochemical localisation studies showed that
PlGF, VEGF, and their receptor, Flt-1, were all localised in
tumour cells. We hypothesised that colon cancer cells secrete
PlGF as well as VEGF and that both factors serve paracrine
and autocrine functions in stimulating angiogenesis as well
as cancer growth and metastasis.
Several clinical efforts are currently underway to evaluate
the therapeutic potential of inhibitors of VEGF or VEGFR-2.
In recent studies, the VEGF specific antibody bevacizumab
prolonged survival of colorectal cancer patients and had a
direct and rapid antivascular effect in human rectal
cancer.27 28 However, VEGF and VEGFR-2 are not only
involved in pathological angiogenesis but also in normal
vessel growth and maintenance.29 Furthermore, VEGF has a
direct effect on motor neurone survival,30 lung maturation,31
liver regeneration,32 control of blood pressure,33 and glomer-
ular development.34 This raises the question of whether long
term inhibition of VEGF may also affect these processes.35
PlGF, in contrast with VEGF, affects blood vessel formation
only under pathological and not under physiological condi-
tions,15 except during normal physiological angiogenesis in
the placenta.36 37 Our results showed that PlGF, but not
VEGF, was significantly upregulated in colorectal cancer and
correlated with survival. Thus PlGF may be a safer
therapeutic target for colorectal cancer.
In summary, we demonstrated that both PlGF and VEGF
expression levels in tumour tissues are higher than in non-
tumour tissues in patients with colorectal cancer. The ratio of
PlGF levels in tumour tissues to PlGF levels in non-tumour
tissues, but not the analogous ratio for VEGF, correlated with
stage of colorectal cancer. We conclude that PlGF expression
correlates with disease progression and survival status, and
may be used as a prognostic indicator for colorectal cancer.
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Liver failure after delivery
Clinical presentation
A 32 year old, gravida 2, para 2, was admitted at 36 weeks’
gestation with upper abdominal pain. During her second
pregnancy she frequently had epistaxis. At 39 weeks’ gesta-
tion she delivered a healthy girl after an elective caesarean
section which was complicated by a total blood loss of
1.5 litres. Progressive liver failure and shock led to her
transport to our hospital one day post partum. She had no
history of alcohol abuse, viral hepatitis, and was not receiving
any medications.
Continuing abdominal bleeding was suspected and at
laparotomy 5 litres of blood were found in the abdominal
cavity from sites of recently lysed adhesions. On day 4 post
partum, liver failure worsened with grade IV encephalopathy
necessary to perform an orthotopic liver transplantation. The
procedure was complicated by severe intraoperative bleeding
(30 litres). A section of the explanted liver is illustrated in
fig 1. Postoperative follow up was complicated by intra-
abdominal infections and steroid refractory chronic rejection
leading to failure of the graft. She was successfully
retransplanted four months later and is currently doing well.
Question
What was the mechanism of liver failure in this patient?
See page 709 for answer
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Epithelial cells disseminate into
the bone marrow of colorectal
adenoma patients
Although the skeleton is not a preferred site
of overt metastasis in colorectal cancer,
demonstration of tumour cells in bone
marrow has to be seen as evidence of the
general disseminative capability of an indivi-
dual tumour.1 Other observations such as
involuntary transmission of tumour by organ
grafts directly supports the notion that very
few quiescent cells lodging at improbable
sites, such as the kidney or heart, suffice to
generate de novo metastatic disease in the
organ recipient.2 The TNM classification
recommends mention of the presence of
disseminated tumour cells as a facultative
factor for metastatisation (M0 (i+) or M0
(mol+)) according to the immunological or
molecular detection technique.3
However, the results of the one and only
meta-analysis available to date show that the
prognostic impact of epithelial cells in the
bone marrow of colorectal cancer patients has
to be substantiated by further studies under
standardised conditions.4 To further investi-
gate this question, bilateral crest aspiration is
performed routinely in our institution for
patients undergoing colorectal surgery for
neoplastic diseases. From September 1997
until July 2000, we investigated 233 patients
using this method: approximately 2 million
mononuclear cells were analysed from each
sample and divided into 10 cytospins. One
half was stained with the A45-B/B3 antibody
(supplied by U Karstens, PhD, Berlin,
Germany) and the other half with Ber-EP4
(Dako, Hamburg, Germany). Staining was
performed using the alkaline phosphatase
anti-alkaline phosphatase technique.
Histopathological staging showed that 15 of
these patients suffered from an early adeno-
carcinoma (T1 category), and in seven
patients no malignancy could be documen-
ted, in spite of complete analysis of the
specimen.
Patients without cancer were of particular
interest to us, for addressing the question of
the early dissemination of epithelial cells in
colorectal neoplasms. To our surprise, we
observed the presence of disseminated
epithelial cells in the bone marrow of three
of these patients (table 1, fig 1).
In a previous study, we examined the
clonality of disseminated tumour cells in
the bone marrow of 51 colorectal cancer
patients by determining the mutational pat-
tern in codons 12 and 13 of the K-ras gene.5
Our results demonstrated that, at least for
K-ras mutations, disseminated epithelial cells
are not always clonal with the primary
tumour. The type of mutations suggested
also that cell dissemination might be an early
event in the development of colorectal neo-
plasms5 as most bone marrow K-ras muta-
tions were found in codon 13, a codon barely
mutated in invasive colorectal cancer but
frequently mutated in aberrant crypt foci.6 7
Obviously, epithelial cells can already dis-
seminate in the polyp stage, in particular
when so-called intraepithelial neoplasia is
diagnosed. Indeed, dissemination of epithe-
lial cells into the bone marrow in a stage
defined as non-cancerous questions the
carcinomatous nature of these cells, and in
particular their micrometastatic nature. In
contrast, should these cells be cancer cells—
which we cannot exclude on the basis of our
previous and present observations—then the
benign nature of intraepithelial neoplasia
should in turn be challenged.
We would be delighted to receive feedback
from other researchers that would help us to
interpret the present observation.
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Table 1 Patients, tumours, and results of bone marrow immunohistochemistry
Sex
Age
(y) Localisation Histopathology A45-B/B3 BerEP4
M 63 Rectum Tubular adenoma with high grade intraepithelial neoplasia Negative Negative
F 41 Colon sigmoideum Tubulovillous adenoma with high grade intraepithelial neoplasia Negative Negative
F 56 Colon ascendens Tubular adenoma with low grade intraepithelial neoplasia Positive Positive
M 57 Colon sigmoideum 3 tubulovillous adenoma with high grade intraepithelial neoplasia Negative Negative
F 67 Rectum Tubulovillous adenoma with high grade intraepithelial neoplasia Negative Negative
M 79 Rectum Tubular adenoma with high grade intraepithelial neoplasia Positive Positive
M 74 Colon sigmoideum Tubulovillous adenoma with high grade intraepithelial neoplasia Negative Positive
2/7 positive 3/7 positive
Figure 1 Disseminated epithelial cells from intraepithelial colorectal neoplasia. Three
disseminated epithelial cells in bone marrow are shown (A45-B/B3, APAAP staining, magnification
4006) and the corresponding large (60645 mm) tubulovillous adenoma of the right colon, with
low grade intraepithelial neoplasia (haematoxylin-eosin staining, magnification 406).
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Genetic evidence that juvenile
nasopharyngeal angiofibroma is
an integral FAP tumour
Juvenile nasopharyngeal angiofibroma (JNA)
is a rare locally invasive neoplasm composed
of cavernous vascular channels set in an
abundant myxoid stroma of fibroblasts and
myofibroblasts.1 2 The histological similarity
to erectile tissue, the almost exclusive occur-
rence in pubescent males, and expression of
multiple steroid receptors suggest that JNA
growth is stimulated by male sex hor-
mones.1 3
The frequency of JNA is significantly
increased in male familial adenomatous
polyposis (FAP) patients, suggesting that it
may arise through alterations of the adeno-
matous polyposis coli (APC)/b-catenin gene
pathway.4 This was supported by the high
frequency of recurrent b-catenin gene muta-
tions detected in sporadic JNA, but no APC
mutations have thus far been found.5–7
We analysed the sequence of the APC gene
and the presence of recurrent b-catenin
mutations in matched blood and tumour
DNA from a 24 year old JNA affected FAP
carrier who underwent restorative proctoco-
lectomy and resection of an abdominal wall
desmoid. The patient was the only JNA
affected sibling of an FAP family. Matched
DNA from blood and from frozen JNA tissue
were analysed for APC mutations using the
TNT Quick Coupled Transcription/Translation
System (Promega, Madison, Wisconsin, USA)
and heteroduplex analysis on agarose mini-
gel,8 followed by sequencing. Using these
techniques we detected a frameshift APC
mutation, c.3927-3931delAAAGA, in both
blood and JNA tissue. This mutation intro-
duces a stop codon (pGlu1309fsX1312) in the
APC gene region between the first and second
20 amino acid b-catenin binding repeats.
Another frameshift APC mutation, consisting
in a 5 bp deletion, c.3183-3187delACAAA,
that introduces a stop codon
(p.Lys1061fsX1062) in the region encoding
the first 20 amino acid b-catenin binding
repeat, was detected only in JNA DNA. Using
restriction enzyme analysis,5 we ruled out the
presence of the JNA associated activating
mutations at codons 32 and 34 in exon 3 of
the b-catenin gene. These results were con-
firmed in duplicate experiments. Due to lack
of tumour sections, we were unable to
perform laser capture microdissection to
separate the vascular and stromal compo-
nents of the tumour. However, the somatic
mutation is expected to have been present in
fibroblasts because of the clear stromal
predominance in the JNA tissue analysed.
In the study by Abraham et al, activating
b-catenin mutations were found in 12 of 16
sporadic JNAs analysed.5 The APC sequence
corresponding to the mutation cluster region
(MCR) of sporadic colorectal cancer9 was
investigated in the four JNAs without
b-catenin mutations but no mutations were
detected.5 Guertl et al analysed 11 sporadic
JNAs from nine patients for mutations in the
MCR of the APC gene and for loss of
heterozygosity (LOH) at the APC locus.6 No
APCmutations were detected and none of the
informative cases were LOH positive.6 Ferouz
et al found no germline APC mutations in a
series of nine JNA patients.7 Thus there was
no direct evidence involving the APC gene in
JNA, although this rare tumour is reported to
occur 25 times more frequently in FAP
affected adolescents than in an age matched
population.4 7
This study documents for the first time the
association between a somatic and a germline
APC mutation in an FAP related JNA.
Because of the stromal predominance in the
tumour analysed (fig 1), the somatic muta-
tion must have been present in the fibroblasts
(that is, in the same cell type where nuclear
accumulation of b-catenin, indicative of acti-
vation of the Wnt pathway, was previously
demonstrated).5 We cannot exclude the pre-
sence or absence of the mutation in the
vascular component. Our findings agree with
the well known evidence of double hit APC
inactivation in FAP associated fibroblastic
tumours.10 Thus FAP associated JNA should
be considered a sex dependent extraintestinal
FAP manifestation.
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Evaluation of vascular signal in
pancreatic ductal carcinoma
using contrast enhanced
ultrasonography: effect of
systemic chemotherapy
Evaluation of the effect of chemotherapy for
pancreatic ductal cancer (PC) is generally
conducted based on changes in tumour
diameter using imaging modalities; however,
exact measurement is often difficult because
of local inflammation, fibrotic change, and
desmoplastic reaction to treatment, leading
to an unreliable evaluation.1 2 PC is consid-
ered a hypovascular tumour. However, newly
developed highly sensitive ultrasonic equip-
ment has enabled the detection of vascular
signals in PC; vascular signals were detected
in 20–67% of cases.3–7 We focused on changes
in tumour vascularity of PC associated with
chemotherapy, and attempted to apply it to
evaluation of the effect of treatment and
usefulness in relation to prognosis. In this
study, we assessed vascular images of the
tumour based on the Doppler signal (v
signal) using contrast enhanced ultrasono-
graphy (CEUS).
Thirty one histopathologically confirmed
consecutive patients with PC who had distant
metastases were included in the study.
Informed consent was obtained from all
patients and the study was approved by the
ethics committee. The tumour was located in
the head of the pancreas in 16 patients and in
the body or tail in 15. All patients were
treated with a combination of S-1, an oral
fluorinated pyrimidine derivative, and gem-
citabine. Chemotherapy was performed every
three weeks as one cycle. CEUS was per-
formed before and after one and two cycles of
treatment using a SSA-770A (Toshiba Co.
Ltd, Tokyo, Japan) and a 3.75 MHz convex
probe. CEUS images were obtained by
Advanced Dynamic Flow mode, which is
wideband Doppler sonography with a high
sensitivity and resolution. The contrast agent
was Levovist (SHU 508 A; Schering AG,
Berlin, Germany), which was administered
at a concentration of 300 mg/ml by intrave-
nous injection of 8 ml at 1 ml/s. After
injection, v signals in the tumour of the
pancreas were continuously observed for
120 seconds. CEUS images showing the high-
est intensity of the vascular signal were
selected and classified into five categories
according to intensity: no signal (grade 0),
spotty signals (grade 1), linear signals
between grades 1 and 3 (grade 2), mosaic
pattern signals (grade 3), and diffuse pattern
signals (grade 4). Dynamic computed tomo-
graphy (CT) was performed with a helical CT
scanner (Light Speed Ultra, GE Medical
Systems) which was performed every two
cycles. In this study, treatment effect after
two cycles of chemotherapy was examined.
The response to treatment, as determined
by dynamic CT after two cycles of treatment,
was as follows: partial response (PR) in five
patients (16%), stable disease (SD) in 17
(55%), and progressive disease (PD) in nine
(29%). A significant decrease in the v signal
score was observed in PR compared with SD
or PD after one cycle of treatment (p=0.0009
and p=0.0017, respectively). After two cycles
of treatment, the decrease was conspicuous
in PR (p=0.0022 and p=0.0021, respec-
tively) whereas in PD a significant increase in
the v signal score was observed compared
with SD (P=0.0160). In univariate analysis,
the increase in v signal (before the second
cycle) was a significant prognostic factor
(p= 0.0150). Median survival time of
patients in the non-increased v signal group
(n=22) after two cycles of treatment was
382 days (71–484) and for those in the
increased group (n=9), 176 days (68–257).
Thus patients in the increased group had a
significantly shorter survival than those in
the non-increased group (p= 0.0094) (fig 1).
In conclusion, analysis of tumour vascu-
larity by CEUS evaluated the effect of
treatment much earlier than dynamic CT,
and predicted prognosis in patients with PC.
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Smoking status in therapeutic
trials in Crohn’s disease
We were interested to hear the results of a
number of trials of novel therapies for
Crohn’s disease (CD) that were presented at
the l2th UEGW and reported in abstract form
in Gut.1–6 Many of the studies were rando-
mised controlled trials in which the active
and control groups were reported to have
identical baseline characteristics. However, in
all of the studies that were reported there was
no mention of the smoking status of the
participants, consistent with recent therapeu-
tic trials in CD published in high profile
journals.7 8 Smoking is a well documented
and universally recognised risk factor for
increased CD severity as smokers are more
likely to relapse and require corticosteroids,
immunosuppressants, and surgery.9 10
Furthermore, smokers are more likely to have
a less favourable response to infliximab.11
Smoking status is therefore a potential
confounding factor in therapeutic trials in
Crohn’s disease. We urge investigators to
include smoking status in the abstract, text,
and analyses of all therapeutic trials of CD.
Furthermore, we believe that stratification
for smoking should be included at the
planning stage for all randomised controlled
trials in CD. Investigators may wish to re-
analyse published data to ensure that results
have not been confounded by smoking.
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Figure 1 Cumulative survival rate according
to changes in the v signal score after two cycles
of treatment. Median survival time (MST) of
patients in the non-increased v signal group
(n = 22) was 382 days (range 71–484) and for
those in the increased group (n = 9), 176 days
(range 68–257). MST in the increased group
was significantly shorter compared with the
non-increased group (log rank test;
p=0.0094).
PostScript 1047
www.gutjnl.com
 on 25 October 2006 gut.bmjjournals.comDownloaded from 
5 Korzenik J, Dieckgraefe B, Valentine J, et al.
Sargramostim induces response and remission in
patients with moderately-to-severely active
Crohn’s disease (CD): results from a randomized,
double-blind, placebo-controlled trial. Gut
2004;53(suppl VI):A49.
6 MacIntosh D, Lukas M, Sandborn W, et al. A
randomized, double blind, placebo-controlled
trial of the clinical assessment of adalimumab
safety and efficacy studied as an induction
therapy in Crohn’s disease (classic). Gut
2004;53(suppl VI):A47.
7 Hanauer SB, Feagan BG, Lichtenstein GR, et al.
Maintenance infliximab for Crohn’s disease: the
ACCENT I randomised trial. Lancet
2002;359:1541–9.
8 Sands B, Anderson F, Bernstein C, et al.
Infliximab maintenance therapy for fistulizing
Crohn’s disease. N Engl J Med 2004;350:934–6.
9 Sutherland LR, Ramcharan S, Bryant H, et al.
Effect of cigarette smoking on recurrence of
Crohn’s disease. Gastroenterology
1990;98:1123–8.
10 Breuer-Katschinski BD, Hollander N, Goebell H.
Effect of smoking on the course of Crohn’s
disease. Eur J Gastroenterol Hepatol
1996;8:225–8.
11 Arnott ID, McNeill G, Satsangi J. An analysis of
factors influencing short-term and sustained
response to infliximab treatment for Crohn’s
disease. Aliment Pharmacol Ther
2003;15:1451–7.
Ferroportin disease due to the
A77D mutation in Australia
Ferroportin disease or type 4 haemochroma-
tosis is an autosomal dominant iron overload
disorder caused by mutations in the iron
exporter ferroportin.1 2 Numerous mutations
in ferroportin (SLC40A1) have been identified
(see review by Pietrangelo3). The A77D
mutation of ferroportin has thus far only been
reported in Italy.2 We report the first A77D
mutation of ferroportin which resulted in
hepatic iron overload in an Australian family.
The study was approved by and performed in
accordance with the ethical standards of the
Queensland Institute of Medical Research
Human Research Ethics Committee and the
Helsinki Declaration of 1975, as revised in
1983. Informed and written consent was
obtained from the patient and family mem-
bers.
The subject, a 45 year old Caucasian male,
presented with complaints of lethargy and
malaise. He had no risk factors for viral
hepatitis, consumed minimal alcohol (20 g/
week), and was married with two children.
Physical examination was normal, including
a normal body mass index.
Initial investigations revealed a haemoglo-
bin level of 12.2 g/dl, white blood count of
3.86103, and platelet count of 1356103.
Serum ferritin concentration was 3500 mg/l
with a transferrin saturation (TS) of 29%.
Molecular analysis did not reveal the pre-
sence of the C282Y, H63D, or S65C mutations
of HFE.
The subject was referred for further eva-
luation after complaining of ongoing lethargy
and fatigue, myalgias, and arthralgia. On
further clinical investigation he was found to
have a mild lymphopenia, an alanine amino-
transferase level of 63 IU/l, a serum ferritin
concentration of 3340 mg/l, and a TS of 29%.
He was non-reactive for hepatitis B surface
antigen and negative for anti-hepatitis C
virus IgG. Random blood sugar level and
lipid profile were normal. HFE analysis was
repeated and again the absence of common
mutations was confirmed.
Liver biopsy was performed and revealed
significant Kupffer cell iron loading with
minimal staining in hepatocytes, as detected
by Perls’ Prussian blue staining. No fibrosis
was detected. Hepatic iron concentration was
96 mmol/g dry weight (normal 5–35 ) with a
hepatic iron index of 2.1 (normal ,1.1). No
other secondary cause for iron loading (for
example, thalassemia, porphyria cutanea
tarda, or chronic liver disease) was detected.
Liver histology and biochemistry were
suggestive of ferroportin disease. The entire
coding region and splice sites of the ferroportin
gene from the proband were polymerase
chain reaction amplified and sequenced, as
previously described.4 Other family members
were subsequently evaluated.
The presence of a cytosine to adenine
change at nucleotide 230 of ferroportin, which
results in mutation of an alanine to aspartic
acid at amino acid 77 (A77D), was identified
in the proband. Subsequently, this change
was also identified in the proband’s father,
sister, and daughter (fig 1). This is the same
mutation which was identified in Italy by
Montosi and colleagues.2 There is no known
ancestral link between the family reported
here and that in Italy. Thus it is likely that the
A77D mutation has occurred in the two
populations separately, as appears to be the
case with the V162del mutation4–8 which has
so far been reported in five geographic
locations.
As knowledge about ferroportin disease is
uncommon in the community, unlike HFE
associated haemochromatosis, it is possible
that some cases of this disorder are not
recognised and thus remain undiagnosed.
This particular case was not diagnosed until
liver biopsy was performed. The raised serum
ferritin level was initially attributed to viral
illness. Because transferrin saturation and
HFE genotype were normal, a diagnosis of
iron overload was not initially considered.
In conclusion, we report the first identifi-
cation of ferroportin disease caused by the
A77D mutation in a region outside of Italy.
This suggests that the A77D mutation may be
more widespread than initially thought. This
report also suggests that some cases of
ferroportin disease may go undiagnosed.
Ferroportin disease should thus be consid-
ered when a patient presents with a high
serum ferritin, even when transferrin satura-
tion and HFE genotype are normal.
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Figure 1 Family pedigree. Family members and their age are shown. The proband is indicated by
an arrow and affected family members by filled shapes. TS, transferrin saturation (%); SF, serum
ferritin concentration (mg/l).
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HHV-8 positive, HIV negative
disseminated Kaposi’s sarcoma
complicating steroid dependent
ulcerative colitis: a successfully
treated case
We present the case of a 49 year old man who
had suffered histologically confirmed ulcera-
tive colitis (UC) since 1998. He had been
asymptomatic for four years when in August
2002 an acute relapse developed.
Colonoscopy and histology of a superficial
bowel specimen showed clear signs of active
UC with no signs of malignancy. Despite
adequate therapy he failed to improve and
was referred for restorative proctocolectomy
because of steroid dependency and end stage
colon. By the time of his referral, violaceous
reddish-brown nodules had developed on his
extremities. Skin biopsy showed spindle cells
and vascular slits. Histological diagnosis was
Kaposi’s sarcoma (KS) of the skin. He
underwent a restorative proctocolectomy
with ileostomy in March 2003. The patholo-
gical examination of the colon showed
features of UC and surprisingly, characteristic
signs of KS also. Human immunodeficiency
virus (HIV) tests were negative. Human
herpesvirus-8 (HHV-8) DNA was detected in
native samples from affected skin but not in
peripheral blood or the large intestine. The
patient recovered rapidly after operation.
Steroid therapy was gradually withdrawn.
Cutaneous lesions regressed completely with
hyperpigmentation, and no new lesions were
observed, despite receiving no treatment
(fig 1).
There are four clinical variants of KS:
classic, endemic, acquired immunodeficiency
syndrome (AIDS) associated, and iatrogenic.1
Excessive use of immunosuppressive drugs in
the second part of the 20th century has been
associated with a higher prevalence of iatro-
genic KS.2 Start of the disease, after admin-
istration of the triggering drug in previously
reported studies, ranged from less than one
month to more than 20 years. The dose of
steroid ranged from 5 to 125 mg/day. There
was no evident correlation between the
development of KS and dose or duration of
steroid therapy.3 Our patient had been treated
with 12–125 mg methylprednisolone daily for
about four months when his skin lesions
appeared. Reduction or discontinuation of
immunosuppressive drugs often leads to
considerable improvement in KS lesions.4 5
In accordance with these data, after with-
drawal of steroid therapy the skin symptoms
of our patient regressed spontaneously.
Visceral KS is quite frequent in AIDS patients
and can affect virtually all viscera, but colonic
KS is rare. These patients are often asympto-
matic or have aspecific symptoms.6 As KS
affects the submucosa more often, superficial
bowel biopsies frequently miss it, as hap-
pened in our case. A link between HHV-8, a
gamma herpesvirus, and KS was first
reported more than 10 years ago.7 8 The virus
was found in more than 90% of KS samples
from HIV seropositive patients but it has low
prevalence in healthy controls. HHV-8 DNA
persists in endothelial cells and spindle cells
of KS. According to the literature, the HHV-8
virus alone is not sufficient to form KS
but it may be an important cofactor in the
development of the disease. In our case, we
detected HHV-8 genome in native samples
from skin lesions but failed to do so in
paraffin embedded colonic samples. The
occurrence of colonic KS and UC together is
rare. We found eight similar cases in the
English literature (table 1).
Our patient was the fourth who was HIV
negative and developed KS in association
with UC. To our knowledge he was the first
proven HHV-8 positive case who developed
disseminated KS during immunosuppressive
treatment for UC. Our treatment policy was
successful. The patient, in spite of his poor
condition, tolerated the surgical therapy well.
After cessation of his steroid therapy KS
regressed spontaneously. He remains well
35 months after surgery.
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Figure 1 (A) Histological signs of ulcerative colitis and Kaposi’s sarcoma (KS) from the resected
colon. Ulcers (blue arrows) at the base of a pseudopolyp and crypt abscesses (red arrows) can be
seen (haematoxylin-eosin staining, 1006magnification). (B) Typical features of KS can be
identified in the submuscular connective tissue layer of the colon (haematoxylin-eosin staining,
4006magnification). (C) Kaposi’s sarcoma on the forearm of the patient, and the same region a
year after operation (D).
Table 1 Main data from previously published articles on the coexistence of colonic Kaposi’s sarcoma (KS) and ulcerative
colitis (UC)
Reference
Year of
publication HIV status Pathology of the colon
Skin
lesion Treatment
Gordon9 1966 No information UC No Colectomy
Adlersberg10 1970 No infoarmation Non-specific colitis No Colectomy
Roth11 1978 No information Segmental non-specific colitis Yes Subtotal colectomy
Weber12 1985 Positive Non-specific colitis of the rectosigmoid
colon, separate lesion in the caecum
Yes Alpha interferon+radiotherapy of rectal KS
Biggs13 1987 Positive UC Yes Urgent colectomy for toxic megacolon and
later abdominoperineal excision for rectal KS
Meltzer14 1987 Negative UC distal to the descendent colon Yes Proctocolectomy with ileostomy
Thompson15 1989 Negative UC No Restorative proctocolectomy
Tedesco16 1999 Negative UC No Restorative proctocolectomy
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CORRECTION
doi: 10.1136/gut.2004.045252
The list of authors for the Editor’s quiz: GI
snapshot on page 672 of the May issue was
published in the incorrect order (CJM de
Groot et al. Liver failure after delivery.
2005;54;672). The correct author list is as
follows: CJM de Groot, GM van Goor, MF
Stolk, G Kazemier, PE Zondervan, HJ
Metselaar, IR Wanless, and HLA Janssen.
EDITOR’S QUIZ: GI SNAPSHOT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Answer
From question on page 927
A 100 mm segment of the proximal jejunum had an irregular
outline, with areas of constriction due to scarring. Histology
(fig 2) showed fibrosis of the subserosa, and interruption and
replacement of the muscularis propria by fibrosis. The
submucosa and epithelium were normal.
The diagnosis was seat belt injury.
Two proposed mechanisms explain the occurrence of small
bowel obstruction after blunt abdominal injury: direct and
indirect. The direct theory postulates that viscera get
compressed between the abdominal wall and spinal column
under the shearing force of the fastened seat belt. In the
healing process, fibrosis causes constrictions that may result
in partial or complete obstruction.
In the indirect mechanism, viscera suffer from ischaemia
secondary to mesenteric injury, with involvement of the
superior and inferior mesenteric arteries. As Miss M’s
mesenteric structures were normal on laparotomy, the
scarring she sustained seems to have been the result of
direct trauma to the gut. The duodenum and jejunum are
particularly vulnerable in the seat belt syndrome because of
their proximity to the vertebral column, as well as their
relation to the fastened seat belt.
The affected segment was excised and this patient was
discharged, totally recovered, nine days after surgery.
doi: 10.1136/gut.2004.058032
Figure 2 Histology of the proximal jejunum. The mucosa and
submucosa are normal, whereas there is interruption of the muscularis
propria, with fibrous scarring (between the arrows). Van Gieson stain,
original magnification6100.
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